EFFICACY AND SAFETY OF OPEN-LABEL CAPLACIZUMAB IN PATIENTS WITH EXACERBATIONS OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING THE PHASE III HERCULES STUDY

被引：0
|
作者：
Peyvandi, F.
Scully, M.
Cataland, S.
Coppo, P.
Knoebl, P.
Kremer Hovinga, J.
Metjian, A.
de la Rubia, J.
Pavenski, K.
Callewaert, F.
Biswas, D.
De Winter, H.
Zeldin, R. K.
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England
[4] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
[5] St Antoine Univ Hosp, Dept Hematol, Paris, France
[6] Vienna Univ Hosp, Div Hematol & Hemostasis, Dept Med 1, Vienna, Austria
[7] Bern Univ Hosp, Univ Clin Hematol, Inselspital, Bern, Switzerland
[8] Bern Univ Hosp, Cent Hematol Lab, Inselspital, Bern, Switzerland
[9] Duke Univ, Sch Med, Div Hematol, Durham, NC USA
[10] Univ Catolica Valencia Hosp Doctor Peset, Hematol Dept, Valencia, Spain
[11] St Michaels Hosp, Dept Lab Med & Pathobiol, Res Inst, Toronto, ON, Canada
[12] Ablynx NV, Clin Dev, Zwijnaarde, Belgium
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO031
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [21] HERCULES - a randomized, double-blind, placebo-controlled, phase 3 study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura
    Knoebl, P.
    Scully, M.
    Cataland, S.
    Peyvandi, F.
    Coppo, P.
    Hovinga, Kremer J.
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    De Winter, H.
    Zeldin, R. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 129 - 130
  • [22] Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
    Peyvandi, F.
    Scully, M.
    Hovinga, J. A. Kremer
    Knoebl, P.
    Cataland, S.
    De Beuf, K.
    Callewaert, F.
    De Winter, H.
    Zeldin, R. K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (07) : 1448 - 1452
  • [23] Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura
    Scully, Marie
    Cataland, Spero R.
    Peyvandi, Flora
    Coppo, Paul
    Knobl, Paul
    Hovinga, Johanna A. Kremer
    Metjian, Ara
    de la Rubia, Javier
    Pavenski, Katerina
    Callewaert, Filip
    Biswas, Debjit
    De Winter, Hilde
    Zeldin, Robert K.
    BLOOD, 2017, 130
  • [24] Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period
    Bruzzese, Antonella
    Vigna, Ernesto
    Martino, Enrica Antonia
    Mendicino, Francesco
    Lucia, Eugenio
    Olivito, Virginia
    Mazzulla, Rosanna
    De Rose, Silvia
    Cozza, Pietro Pasquale
    Bova, Carlo
    Filippelli, Gianfranco
    Zinno, Francesco
    Morelli, Michele
    Morabito, Fortunato
    Gentile, Massimo
    BLOOD COAGULATION & FIBRINOLYSIS, 2023, 34 (03) : 215 - 217
  • [25] Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura
    Sargentini-Maier, Maria Laura
    De Decker, Philip
    Tersteeg, Claudia
    Canvin, Jan
    Callewaert, Filip
    De Winter, Hilde
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (06) : 537 - 545
  • [26] Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study
    Hovinga, Johanna A. Kremer
    Scully, Marie
    Cataland, Spero R.
    Peyvandi, Flora
    Coppo, Paul
    Knoebl, Paul
    De La Rubia, Javier
    Pavenski, Katerina
    Minkue, Jessica
    Sousa, Rui Passos
    Callewaert, Filip
    De Winter, Hilde
    Metjian, Ara
    BLOOD, 2018, 132
  • [27] RESULTS OF THE RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PHASE 3 HERCULES STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP)
    Peyvandi, F.
    Scully, M.
    Cataland, S.
    Coppo, P.
    Knoebl, P.
    Hovinga, J. Kremer
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    De Winter, H.
    Zeldin, R. K.
    HAEMATOLOGICA, 2018, 103 : S31 - S31
  • [28] A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
    Scully, Marie
    McDonald, Vickie
    Cavenagh, Jamie
    Hunt, Beverley J.
    Longair, Ian
    Cohen, Hannah
    Machin, Samuel J.
    BLOOD, 2011, 118 (07) : 1746 - 1753
  • [29] Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
    He, Jingyi
    Qi, Jiaqian
    Han, Haohao
    Xu, Xiaoyan
    Li, Xueqian
    Song, Xiaofei
    Han, Yue
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (05) : 377 - 385
  • [30] Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
    Voelker, Linus A.
    Brinkkoetter, Paul T.
    Knoebl, Paul N.
    Krstic, Miroslav
    Kaufeld, Jessica
    Menne, Jan
    Buxhofer-Ausch, Veronika
    Miesbach, Wolfgang
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (11) : 3061 - 3066
12345